Zydus Lifesciences Limited (including its subsidiaries / affiliates, hereinafter referred to as "Zydus") has received final approval for Lubiprostone Capsules, 8 mcg and 24 mcg (USRLD: Amitiza® Capsules) from the United States Food and Drug Administration (USFDA).
Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation). The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).
Lubiprostone Capsules, 8 mcg and 24 mcg had annual sales of USD 196.5 mn in the United States (IQVIA MAT, January 2023).
The group now has 354 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 482.35 as compared to the previous close of Rs. 478.55. The total number of shares traded during the day was 36697 in over 1419 trades.
The stock hit an intraday high of Rs. 484.50 and intraday low of 478.20. The net turnover during the day was Rs. 17640470.00.
(*as of 31st December 2022)